• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aldeyra Therapeutics, Inc. (Amendment)

    1/4/22 9:44:44 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email
    SC 13G/A 1 s13ga_122721-aldeyra.htm SCHEDULE 13G/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
    _____________________

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 2)1

    Aldeyra Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    01438T106
    (CUSIP Number)
     
    December 31, 2021
    Date of Event Which Requires Filing of this Statement


    Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

    [   ] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [X] Rule 13d-1(d)

    _______________________

    1The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.






    1




    CUSIP No. 01438T106


    1)
    Name of Reporting Person
    I.R.S. Identification No. of Above Person (Entities Only) (Voluntary)
     
    Domain Partners VI, L.P.
     
    2)
    Check the Appropriate Box if a Member of a Group
    (a) [X]
    (b) [   ]

    3)
    SEC Use Only


     
    4)
    Citizenship or Place of Organization

    Delaware
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With

    5)
    Sole Voting Power

    -0-
    6)
    Shared Voting Power

    -0-
    7)
    Sole Dispositive Power

    -0-
    8)
    Shared Dispositive Power

    -0-
    9)
    Aggregate Amount Beneficially Owned by Each Reporting Person

    -0-
    10)
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    [   ]
    11)
    Percent of Class Represented by Amount in Row (9)

    -0-
    12)
    Type of Reporting Person

    PN







    2




    CUSIP No. 01438T106


    1)
    Name of Reporting Person
    I.R.S. Identification No. of Above Person (Entities Only) (Voluntary)
     
    DP VI Associates, L.P.
     
    2)
    Check the Appropriate Box if a Member of a Group


    (a) [X]
    (b) [   ]
    3)
    SEC Use Only


     
    4)
    Citizenship or Place of Organization

    Delaware
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With

    5)
    Sole Voting Power

    -0-
    6)
    Shared Voting Power

    -0-
    7)
    Sole Dispositive Power

    -0-
    8)
    Shared Dispositive Power

    -0-
    9)
    Aggregate Amount Beneficially Owned by Each Reporting Person

    -0-
    10)
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    [   ]
    11)
    Percent of Class Represented by Amount in Row (9)

    -0-
    12)
    Type of Reporting Person

    PN







    3




    CUSIP No. 01438T106

    Amendment No. 2 to Schedule 13G (Final Amendment)

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons on February 5, 2015 and Amendment No. 1 thereto filed on January 9, 2020 (as so amended, the “Schedule 13G”).  Terms defined in the Schedule 13G are used herein as so defined.

    The following items of the Schedule 13G are hereby amended and restated as follows:

    Item 2(b) – Address of Principal Business Office:

    103 Carnegie Center, Suite 300, Princeton, NJ 08540

    Item 4 – Ownership:

    (a) through (c)  The information requested in these paragraphs is incorporated herein by reference to the cover pages to this Amendment No. 2 to Schedule 13G.

    Item 5 – Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the Common Stock, check the following:  [X]






    4




    CUSIP No. 01438T106

    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

    Dated:  January 4, 2022


     
    DOMAIN PARTNERS VI, L.P.

     
     
    By:
    One Palmer Square Associates VI, L.L.C., General Partner
     
     
     
    By:
    /s/ Lisa A. Kraeutler
     
       
    Attorney-in-Fact


     
     
    DP VI ASSOCIATES, L.P.

     
     
    By:
    One Palmer Square Associates VI, L.L.C., General Partner

     
     
    By:
    /s/ Lisa A. Kraeutler
     
       
    Attorney-in-Fact
     









    5
    Get the next $ALDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX

    DatePrice TargetRatingAnalyst
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    4/2/2024$10.00Buy
    H.C. Wainwright
    4/27/2022$15.00Buy
    H.C. Wainwright
    12/21/2021$25.00 → $21.00Buy
    Citigroup
    12/21/2021$24.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aldeyra Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00

    4/3/24 7:39:55 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00

    4/2/24 8:09:59 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00

    4/27/22 7:14:02 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    10/21/24 8:22:37 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $833,867 worth of shares (177,993 units at $4.68) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    4/8/24 5:32:55 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Machatha Stephen sold $113,713 worth of shares (22,073 units at $5.15), decreasing direct ownership by 9% to 221,799 units (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/13/25 6:03:44 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Walker Neal

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    6/12/25 4:36:38 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide. "Although retinitis pigmentosa is a relentlessly progressive condition that has been recognized for decades as a significant cause of blindness, there are no approved therapies for

    8/19/25 7:01:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Dr. Brady's conversation with Matthew Caufield, Director, Equity Research at H.C. Wainwright & Co., is scheduled to begin at 10:30 a.m. ET Wednesday, August 13, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following

    8/6/25 7:01:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide and remains a significant cause of inherited blindness. "Retinitis pigmentosa is a serious and incurable sight-threatenin

    7/24/25 7:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    SEC Filings

    View All

    Aldeyra Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    8/19/25 7:00:27 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.

    SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    8/14/25 4:21:34 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aldeyra Therapeutics Inc.

    10-Q - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    8/7/25 4:03:13 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Leadership Updates

    Live Leadership Updates

    View All

    Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

    4/17/25 7:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    2/14/24 4:52:01 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

    SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    2/13/24 4:58:48 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    Financials

    Live finance-specific insights

    View All

    Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

    In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

    5/5/25 6:34:00 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

    5/5/25 4:00:00 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

    Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

    4/3/25 8:00:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care